Alzheimer's disease (AD) is characterized by an extensive accumulation of amyloid-β (Aβ)
peptide, which triggers a set of deleterious processes, including synaptic dysfunction,
inflammation, and neuronal injury, leading to neuronal loss and cognitive impairment. A
large body of evidence supports that nuclear receptor (NR) activation could be a promising
therapeutic approach for AD. NRs are ligand-activated transcription factors that regulate
gene expression and have cell type-specific effects. In this review, we discuss the …